Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Comparative Safety and Efficacy of Posttransplant Cyclophosphamide Versus Antithymocyte Globulin in Patients with Cardiovascular Comorbidity Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in First Complete Remission from Unrelated Donors: A Retrospective Pair-Match Analysis of EBMT ALWP

Jan Vydra, Allain-Thibeault Ferhat, Nicolaus Kröger, Tobias Gedde-Dahl, Matthias Eder, Thomas Schroeder, Urpu Salmenniemi, Gerard Socie, Jakob Passweg, Sr., Ibrahim Yakoub-Agha, Alessandro Rambaldi, Robert Zeiser, Matthias Stelljes, Kristina Carlson, Cristina Castilla-Llorente, Alexandros Spyridonidis, Fabio Ciceri, Mohamad Mohty

Blood (2024) 144 (Supplement 1): 2161.

https://doi.org/10.1182/blood-2024-198999

Published: 2024

Journal Articles

Prediction of Poor Survival after Hematopoietic Cell Transplantation in Myelofibrosis Using Machine Learning Techniques

Blood (2024) 144 (Supplement 1): 3558.

https://doi.org/10.1182/blood-2024-200237

Published: 2024

Journal Articles

Efficacy of Carvykti in Cartitude-4 Versus Alternative Treatments from Daratumumab Clinical Trials for the Treatment of Patients with Lenalidomide-Refractory Multiple Myeloma

Michel Delforge, Irit Avivi Mazza, Maria- Victoria Mateos, Kristina Carlson, Keqin Qi, João Mendes, Seina Lee, Jordan M. Schecter, William Deraedt, Carolina Lonardi, Ana Slaughter, Diana Chen, Man Zhao, Kaitlyn Connors, Nitin Patel, Erika Florendo, Hermann Einsele, Binod Dhakal, Wilfried Roeloffzen

Blood (2024) 144 (Supplement 1): 7085.

https://doi.org/10.1182/blood-2024-201606

Published: 2024

Journal Articles

In AML Patients Allografted in First Remission, DNMT3A Mutations Differentially Affect Post-Transplant Outcomes According to Karyotype, NPM1 and FLT3-ITD Mutation Status - from the EBMT-ALWP

Blood (2024) 144 (Supplement 1): 4315.

https://doi.org/10.1182/blood-2024-202764

Published: 2024

Journal Articles

Risk of Infections in Multiple Myeloma in the Era of Novel Agents, a Population-Based Study Based on 8672 Multiple Myeloma Patients Diagnosed 2008-2021 from the Swedish Myeloma Registry

Cecilie Hveding Blimark, Kristina Carlson, Christopher Day, Sigrun Einarsdottir, Gunnar Juliusson, Moshtak Karma, Dorota Knut-Bojanowska, Gunnar Larfors, Ingemar Turesson, Mariana Villegas Scivetti, Ingigerdur Sverrisdottir

Blood (2023) 142 (Supplement 1): 4696.

https://doi.org/10.1182/blood-2023-174228

Published: 2023

Journal Articles

Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

Blood (2022) 140 (Supplement 1): 400–402.

https://doi.org/10.1182/blood-2022-159009

Published: 2022

Journal Articles

Comparative Study of Unrelated and Haploidentical Donor Hematopoietic Cell Transplant for Chronic Myeloid Leukemia with Post Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis: A Study from the Chronic Malignancies Working Party of EBMT

Blood (2021) 138 (Supplement 1): 3954.

https://doi.org/10.1182/blood-2021-147684

Published: 2021

Journal Articles

A Prospective Phase 2 Study to Assess Minimal Residual Disease after Ixazomib, Lenalidomide and Dexamethasone Treatment for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-138643

Published: 2020

Journal Articles

A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance after Induction with Carfilzomib-Cyclophosphamide-Dexamethasone in Salvage ASCT in Multiple Myeloma: A Trial By the Nordic Myeloma Study Group

Blood (2019) 134 (Supplement_1): 601.

https://doi.org/10.1182/blood-2019-122141

Published: 2019

Journal Articles

Incidence and Outcome in Aplastic Anemia Diagnosed 2000-2011 - a Nationwide Swedish Registry Study

Krista Vaht, MD, Magnus Göransson, MD PhD, Kristina Carlson, MD PhD, Cecilia Isaksson, MD, Stig Lenhoff, Anna Sandstedt, MD, Bertil Uggla, MD PhD, Per T. Ljungman, MD PhD, Mats Brune, MD PhD, Per-Ola Andersson, MD PhD

Blood (2016) 128 (22): 3905.

https://doi.org/10.1182/blood.V128.22.3905.3905

Published: 2016

Journal Articles

Family Mismatched Donor Transplantation for Myelofibrosis: A Retrospective Analysis of the EBMT Chronic Leukaemia Working Party

Kavita Raj, MD PhD, Eduardo Olavarria, Diderik-Jan Eikema, Liesbeth C de Wreede, PhD, Linda Koster, Maria Teresa van Lint, Fabio Ciceri, MD, Jakob Passweg, MD, Nicolaas PM Schaap, MD PhD, Kristina Carlson, MD PhD, Didier Blaise, MD PhD, Stella Santarone, MD, Antonin Vitek, MD PhD, Jose L. Diez-Martin, MD PhD, Donal McLornan, MB, Bch (Hons), PhD MRCP, FRCPath, Marie Robin, MD PhD, Yves Chalandon, MD, Nicolaus Kroeger, MD

Blood (2016) 128 (22): 4655.

https://doi.org/10.1182/blood.V128.22.4655.4655

Published: 2016

Journal Articles

Outcome Of Pregnancy After Autologous Hematopoietic Stem Cell Transplantation (AHSCT) For Autoimmune Diseases (AD): A Retrospective Study Of The EBMT Autoimmune Diseases Working Party (ADWP)

Emilian Snarski, John A Snowden, MD, FRCP, FRCPath, Manuela Badoglio, Kristina Carlson, Joachim Burman, MD, Maria Carolina Oliveira, John Moore, Jeffrey Tan, Montserrat Rovira, MD, Richard E Clark, MD, Albert Saiz, Sondess Hadj Khelifa, Alessandra Crescimanno, Lynne Laing, Maurizio Musso, Thierry Martin, Dominique Farge, MD

Blood (2013) 122 (21): 4640.

https://doi.org/10.1182/blood.V122.21.4640.4640

Published: 2013

Journal Articles

Center Experience and Calendar Year Of Transplantation Strongly Influence Short Term Survival After Autologous Peripheral Blood Transplantation In 1315 Patients With Light Chain Amyloidosis: An EBMT Analysis

Stefan O Schonland, MD, Ute Hegenbart, MD, Simona Iacobelli, Ph. D., Jennifer Hoek, M Rovira, Guustaaf van Imhoff, G Bandini, Ulf-Henrik Mellqvist, MD, PhD, Veronique Leblond, MD, Kristina Carlson, Samo Zver, MD, Ph.D, Didier Blaise, MD, Emilio Paolo Alessandrino, MD, Laurent Garderet, Nicolaus Kröger, MD

Blood (2013) 122 (21): 417.

https://doi.org/10.1182/blood.V122.21.417.417

Published: 2013

Journal Articles

Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial

Blood (2013) 121 (23): 4647–4654.

https://doi.org/10.1182/blood-2012-11-464503

Published: 2013

Journal Articles

Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT

Esa Jantunen, Ariane Boumendil, Herve Finel, Jian-Jian Luan, Peter Johnson, Alessandro Rambaldi, Andrew Haynes, Michel A. Duchosal, Wolfgang Bethge, Pierre Biron, Kristina Carlson, Charles Craddock, Claudius Rudin, Jurgen Finke, Gilles Salles, Frank Kroschinsky, Anna Sureda, Peter Dreger

Blood (2013) 121 (13): 2529–2532.

https://doi.org/10.1182/blood-2012-11-466839

Published: 2013

Includes: Supplemental data

Journal Articles

New autoimmune diseases after cord blood transplantation: a retrospective study of EUROCORD and the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation

Blood (2013) 121 (6): 1059–1064.

https://doi.org/10.1182/blood-2012-07-445965

Published: 2013

Includes: Supplemental data

Journal Articles

Is Multiple Myeloma a Chronic Disease? A Population Based Study Comparing 1843 Patients to a Matched Swedish Population.

Hareth Nahi, Johan Liwing, Anders Aldrin, Johan Andreasson, Cecilie Blimark, MD, Kristina Carlson, Jon Enestig, Max Flogegård, Karin Forsberg, Astrid Gruber, MD, PhD, Peter Johansson, MD, PhD, Helene Kviele, Birgitta Lauri, Ulf-Henrik Mellqvist, MD, PhD, Per Näsman, Agneta Swedin, Magnus Svensson, Katarina Uttervall, MD, PhD-student, Johan Aschan, MD, PhD

Blood (2012) 120 (21): 2970.

https://doi.org/10.1182/blood.V120.21.2970.2970

Published: 2012

Journal Articles

Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma

Blood (2010) 116 (9): 1405–1412.

https://doi.org/10.1182/blood-2009-08-237974

Published: 2010

Journal Articles

Randomised Study on Prophylactic Pamidronate 30 mg vs. 90 mg in Multiple Myeloma (Nordic Myeloma Study Group).

Peter Gimsing, MD, Kristina Carlson, MD, Peter Fayers, Ingemar Turesson, MD, Finn Wisløff

Blood (2007) 110 (11): 533.

https://doi.org/10.1182/blood.V110.11.533.533

Published: 2007

Journal Articles

IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G 2 /M-phase accumulation and apoptosis in multiple myeloma cells

Thomas Strömberg, Simon Ekman, Leonard Girnita, Lina Y. Dimberg, Olle Larsson, Magnus Axelson, Johan Lennartsson, Ulf Hellman, Kristina Carlson, Anders Österborg, Karin Vanderkerken, Kenneth Nilsson, Helena Jernberg-Wiklund

Blood (2006) 107 (2): 669–678.

https://doi.org/10.1182/blood-2005-01-0306

Published: 2006

Includes: Supplemental data

NARROW

Prediction of Poor Survival after Hematopoietic Cell Transplantation in Myelofibrosis Using Machine Learning Techniques

Efficacy of Carvykti in Cartitude-4 Versus Alternative Treatments from Daratumumab Clinical Trials for the Treatment of Patients with Lenalidomide-Refractory Multiple Myeloma

In AML Patients Allografted in First Remission, DNMT3A Mutations Differentially Affect Post-Transplant Outcomes According to Karyotype, NPM1 and FLT3-ITD Mutation Status - from the EBMT-ALWP

Risk of Infections in Multiple Myeloma in the Era of Novel Agents, a Population-Based Study Based on 8672 Multiple Myeloma Patients Diagnosed 2008-2021 from the Swedish Myeloma Registry

Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

Comparative Study of Unrelated and Haploidentical Donor Hematopoietic Cell Transplant for Chronic Myeloid Leukemia with Post Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis: A Study from the Chronic Malignancies Working Party of EBMT

A Prospective Phase 2 Study to Assess Minimal Residual Disease after Ixazomib, Lenalidomide and Dexamethasone Treatment for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance after Induction with Carfilzomib-Cyclophosphamide-Dexamethasone in Salvage ASCT in Multiple Myeloma: A Trial By the Nordic Myeloma Study Group

Incidence and Outcome in Aplastic Anemia Diagnosed 2000-2011 - a Nationwide Swedish Registry Study

Family Mismatched Donor Transplantation for Myelofibrosis: A Retrospective Analysis of the EBMT Chronic Leukaemia Working Party

Outcome Of Pregnancy After Autologous Hematopoietic Stem Cell Transplantation (AHSCT) For Autoimmune Diseases (AD): A Retrospective Study Of The EBMT Autoimmune Diseases Working Party (ADWP)

Center Experience and Calendar Year Of Transplantation Strongly Influence Short Term Survival After Autologous Peripheral Blood Transplantation In 1315 Patients With Light Chain Amyloidosis: An EBMT Analysis

Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial

Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT

New autoimmune diseases after cord blood transplantation: a retrospective study of EUROCORD and the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation

Is Multiple Myeloma a Chronic Disease? A Population Based Study Comparing 1843 Patients to a Matched Swedish Population.

Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma

Randomised Study on Prophylactic Pamidronate 30 mg vs. 90 mg in Multiple Myeloma (Nordic Myeloma Study Group).

IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G 2 /M-phase accumulation and apoptosis in multiple myeloma cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only